EC Number   |
General Information |
Reference |
|---|
   2.1.1.348 | drug target |
activators of METTL3-14-WTAP can be potential anticancer agents against glioblastoma |
756405 |
| 2.1.1.348 | drug target |
m6A modification may be a target for antivirals of enterovirus 71 (EV71) |
757858 |
| 2.1.1.348 | drug target |
METTL3 is probably involved in pancreatic carcinogenesis. It could eventually be a prognostic marker or a therapeutic target for pancreatic cancer |
757908 |
| 2.1.1.348 | drug target |
METTL3 may be an effective therapeutic target for bone tissue repair and regeneration |
757658 |
| 2.1.1.348 | drug target |
targeting m6A through its writer enzyme METTL3 may represent a therapeutic strategy for managing maladaptive cardiac hypertrophy and remodeling during the progression of heart failure |
756496 |
| 2.1.1.348 | drug target |
the enzyme (METTL3) contributes to transforming growth factor-beta-induced epithelial-mesenchymal transition of lung cancer cells through the regulation of JUNB. The significance of the regulation for m6A RNA modification in the important step of cancer progression provides the possibility to develop therapeutic strategies for the treatment of cancer metastasis |
755988 |
| 2.1.1.348 | drug target |
the enzyme (METTL3) may be a therapeutic target which is potential to be used for the treatment of human osteosarcoma |
755980 |
| 2.1.1.348 | malfunction |
conditional knockout of the m6A methyltransferase Mettl3 in bone marrow mesenchymal stem cells induces pathological features of osteoporosis in mice. Mettl3 loss-of-function results in impaired bone formation, incompetent osteogenic differentiation potential and increased marrow adiposity. Knockout of Mettl3 reduces the translation efficiency of mesenchymal stem cell lineage allocator Pth1r, and disrupts the PTH-induced osteogenic and adipogenic responses in vivo |
757777 |
| 2.1.1.348 | malfunction |
deleting the enzyme (Mettl3) from the adult haematopoietic system leads to an accumulation of haematopoietic stem cell in the bone marrow and marked reduction of reconstitution potential due to a blockage of haematopoietic stem cell differentiation. Deleting Mettl3 from myeloid cells using Lysm-cre does not impact myeloid cell number or function. m6A sequencing reveals 2073 genes with significant m6A modification in haematopoietic stem cells |
757726 |
| 2.1.1.348 | malfunction |
depleting METTL3 in mouse hippocampus reduces memory consolidation ability, yet unimpaired learning outcomes can be achieved if adequate training is given or the m6A methyltransferase function of METTL3 is restored |
756408 |
